CX3CL1 and type 2 diabetes mellitus: Met therapeutic effects in lowering hyperglycemia in obese people, those with T2DM, or those with impaired glucose tolerance may be mostly linked to decreased TNF-α and CX3CL1 production (Szukiewicz et al. 2018).